Aratana Therapeutics (PETX) Tops Q2 EPS by 37c

Aratana Therapeutics (NASDAQ: PETX) reported Q2 EPS of $0.61, $0.37 better than the analyst estimate of $0.24. Revenue for the quarter came in at $38.05 million versus the consensus estimate of $7.61 million.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Is Treasury selloff a major issue for stock market bulls?
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c